Here are Friday's biggest analyst calls: Nvidia, SpaceX, Apple, Tesla, Meta, AMD, BP, Costco, Nike & more
Analysts made multiple rating changes: Wells Fargo initiated Johnson Controls (JCI) as overweight, UBS initiated Chemed (CHE) as buy, Mizuho reiterated SpaceX as outperform, Barclays initiated Ligand Pharmaceuticals (LGND) as overweight, Seaport reiterated Nvidia (NVDA) as sell, UBS upgraded Stem (STEM) to buy, HSBC upgraded BP (BP) to buy, Bernstein initiated CF Industries (CF) as outperform, Bank of America reiterated AMD (AMD) as buy, Bernstein reiterated Apple (AAPL) as outperform, JPMorgan…
How this was made
The 30-second read
Why it matters
Collective analyst sentiment shifts can influence short‑term price action, but individual impact varies by company.
Market read
Analyst coverage changes provide fresh directional cues for the listed stocks mentioned.
What to watch
Potential macro headwinds from inflation and rate uncertainty could dampen upside.
Background
The article compiles a series of analyst initiations, upgrades, and downgrades across multiple U.S.-listed companies.
Ticker impact
Wells Fargo initiates coverage of Johnson Controls at Overweight, citing record backlog and margin visibility.
moderate upside
Analyst upgrade with price target implies near‑term price lift.
UBS initiates coverage of Chemed with a Buy rating, calling the hospice services business attractive at current levels.
moderate upside
New coverage often triggers short‑term buying pressure.
Barclays initiates Ligand Pharmaceuticals at Overweight, highlighting its royalty aggregation model.
moderate upside
Analyst overweight can attract institutional interest.
Needham initiates PDF Solutions as Buy, noting the company's under‑understood analytics business.
moderate upside
New coverage with a target price often triggers buying.
Truist upgrades First Financial Bancorp to Buy from Hold, citing benefit from rising rates.
moderate upside
Upgrade aligns with macro rate environment.
Seaport reiterates Nvidia as Sell, warning limited upside due to capacity constraints.
potential downside
Negative stance from a research house can dampen momentum.
UBS upgrades Stem to Buy from Neutral after 2Q26 shows earnings inflection.
moderate upside
Upgrade tied to clear earnings improvement.
Mizuho initiates Tower Semiconductor at Outperform with a $300 price target.
moderate upside
Positive rating and target may attract buyers.
Market effects
Broad analyst upgrades may lift technology and industrial sectors.
U.S. equities could see modest buying pressure across covered names.
Limited to U.S. listed companies; no global macro effect.
Counterpoint
Many upgrades may be priced in; downside risk remains if earnings miss expectations.
Key entities
- Research FirmWells Fargo
Initiated JCI at Overweight.
- Research FirmUBS
Initiated CHE and upgraded STEM.
- Research FirmBarclays
Initiated LGND, upgraded BP and HUM.
